Change in MAPSE During Treatment of Sepsis

Launched by UNIVERSITY OF MARYLAND, BALTIMORE · Nov 22, 2022

Keywords

ClinConnect Summary

This clinical trial is studying how a specific heart measurement changes in patients with sepsis, a serious condition caused by infections in the bloodstream. Researchers want to see if treatment for septic shock improves the heart's ability to pump blood by looking at a measurement called MAPSE, which shows how well the heart's mitral valve is moving. To do this, they will use an ultrasound, a safe and painless imaging technique, to take pictures of the heart and measure MAPSE before and after treatment.

To participate in this study, patients must be diagnosed with sepsis or septic shock and be between the ages of 18 and 74. Unfortunately, those who are under 18, currently in the emergency department, or unable to give consent are not eligible. Participants can expect to have an ultrasound done to measure their heart function at the beginning of the study and again after they receive treatment for their infection. This trial aims to help improve our understanding of how sepsis affects the heart and how treatment can help patients recover.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Diagnosis of Sepsis or Septic Shock
• Exclusion Criteria:
• • Age equal to or less than 17
• • patient in the emergency department
• • Unable to perform POCUS exam due to medical necessity
• • Patients without sepsis
• • unable to obtain consent or have a legal representative consent